Melanoma tumour vasculature heterogeneity: from mice models to human.
Endothelium
Melanoma
Microcirculation
Tumour vasculature heterogeneity
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
05
09
2018
accepted:
30
11
2018
pubmed:
14
12
2018
medline:
8
3
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
Tumour angiogenesis is defined by an anarchic vasculature and irregularities in alignment of endothelial cells. These structural abnormalities could explain the variability in distribution of nanomedicines in various tumour models. Then, the main goal of this study was to compare and to characterize the tumour vascular structure in different mouse models of melanoma tumours (B16F10 and SK-Mel-28) and in human melanomas from different patients. Tumours were obtained by subcutaneous injection of 10
Identifiants
pubmed: 30547320
doi: 10.1007/s00432-018-2809-z
pii: 10.1007/s00432-018-2809-z
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-597Subventions
Organisme : Ligue Contre le Cancer
ID : 2016
Organisme : Erasmus+
ID : 2015
Références
Microcirculation. 1999 Mar;6(1):7-22
pubmed: 10100186
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Am J Pathol. 2000 Apr;156(4):1363-80
pubmed: 10751361
Jpn J Cancer Res. 2000 Feb;91(2):261-9
pubmed: 10761715
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
J Control Release. 2001 Jul 6;74(1-3):7-25
pubmed: 11489479
J Clin Oncol. 2002 Apr 1;20(7):1826-31
pubmed: 11919240
Mol Cancer Ther. 2002 Jun;1(8):617-28
pubmed: 12479222
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
pubmed: 12516034
Nat Immunol. 2003 Dec;4(12):1164-5
pubmed: 14639465
Histopathology. 2004 May;44(5):428-36
pubmed: 15139990
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Curr Opin Genet Dev. 2005 Feb;15(1):102-11
pubmed: 15661540
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
Jpn J Cancer Res. 1991 Nov;82(11):1309-16
pubmed: 1752787
Semin Oncol. 2007 Dec;34(6):467-75
pubmed: 18083370
Br J Cancer. 2009 Mar 24;100(6):865-9
pubmed: 19240721
J Mol Med (Berl). 2009 Jun;87(6):561-9
pubmed: 19455291
Nat Med. 2009 Oct;15(10):1219-23
pubmed: 19749772
Int J Cancer. 2010 Nov 15;127(10):2279-91
pubmed: 20143398
Dev Cell. 2010 Jun 15;18(6):884-901
pubmed: 20627072
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Curr Opin Genet Dev. 2011 Feb;21(1):73-9
pubmed: 21106363
Adv Drug Deliv Rev. 2011 Jul 18;63(8):623-39
pubmed: 21144874
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Lett. 2011 Aug 1;307(1):62-71
pubmed: 21481528
Dev Cell. 2011 Aug 16;21(2):193-215
pubmed: 21839917
J Control Release. 2012 Jul 20;161(2):175-87
pubmed: 21945285
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006536
pubmed: 22393533
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Oral Dis. 2013 Sep;19(6):620-7
pubmed: 23279259
Cancer Chemother Pharmacol. 2013 Aug;72(2):417-27
pubmed: 23797686
Cancer Cell Int. 2013 Jul 26;13:75
pubmed: 23890195
J Control Release. 2013 Nov 28;172(1):12-21
pubmed: 23920039
J Control Release. 2013 Dec 28;172(3):1045-64
pubmed: 24096014
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18632-7
pubmed: 24167277
Head Neck. 2015 Nov;37(11):1596-602
pubmed: 24931916
Int J Pharm. 2015 Feb 20;479(2):399-407
pubmed: 25578367
Int J Exp Pathol. 2015 Apr;96(2):73-80
pubmed: 25664478
Nanomedicine. 2015 Nov;11(8):1893-907
pubmed: 26282377
J Nucl Med. 2016 Apr;57(4):601-7
pubmed: 26719375
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
Epigenetics. 2009 Jul 1;4(5):313-321
pubmed: 28001118
Trends Cancer. 2017 Aug;3(8):561-570
pubmed: 28780933
Cancer Cell. 2017 Nov 13;32(5):669-683.e5
pubmed: 29136509
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32
pubmed: 3191477
J Natl Cancer Inst. 1984 Jan;72(1):145-50
pubmed: 6582294
Semin Cutan Med Surg. 1996 Dec;15(4):336-48
pubmed: 9069601